JPRN-UMIN000005086已完成2 期
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutation - Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutation
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 21 人开始时间: 2011年2月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients having EGFR gene mutation (T790M) 2) Past history of drug hypersensitivity 3) Patients with superior vena cava (SVC) syndrome 4) pulmonary fibrosis or interstitial pneumonitis evident on chest CT 5) serious heart dosease 6) Psychiatric disorder 7) uncontrollable diabetes 8) paresis of intestine, intestinal obstruction 9) Patients with active severe infections 10) serious complications other 11) Patients with active concomitant malignancy 12) Pregnant or lactation women, or women with known or suspected pregnancy 13) Inappropriate to entry by physician
研究者
相似试验
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
已完成
2 期
Phase II trial of gefitinib plus pemetrexed after the relapse to gefitinib in the patients with non-small-cell lung cancer harboring EGFR gene mutations.SCLCJPRN-UMIN000010709Hanshin-Saga Collaborative Cancer Study Group45
已完成
不适用
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33